NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Xu, Heng; Gu, Na; Liu, Zhaobo; Zheng, Min; Xiong, Fang; Wang, Siying; Li, Ning; Lu, Jun

doi:10.3892/ol.2011.441

Cited by 23 publications

(23 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,14,15 Recent reports have shown that NY-ESO-1 expression in hepatocellular carcinoma is associated with disease recurrence following surgical resection, possibly mediated by enhanced migratory ability conferred by NY-ESO-1. 16 Furthermore, the same study and others have implicated NY-ESO-1 as a possible prognostic marker in certain tumor types. 8,16,17 Importantly, the expression of cancer testis antigens by tumors enables the use of targeted immunotherapy, which has shown promise in clinical studies.…”

Section: Discussionmentioning

confidence: 99%

“…16 Furthermore, the same study and others have implicated NY-ESO-1 as a possible prognostic marker in certain tumor types. 8,16,17 Importantly, the expression of cancer testis antigens by tumors enables the use of targeted immunotherapy, which has shown promise in clinical studies. [18][19][20][21] Variable NY-ESO-1 expression has been described in many malignancies, including melanoma, neuroblastoma, sarcomas, and a variety of carcinomas, such as esophageal, breast, prostate, lung, endometrial, ovarian, uterine, and bladder.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms

Hemminger

Iwenofu

2013

Modern Pathology

View full text Add to dashboard Cite

Myxoid and round cell liposarcomas constitute approximately one-third of all liposarcomas, a relatively common group of fat-derived soft tissue sarcomas. The histomorphology is a continuum between highly differentiated myxoid and poorly differentiated round cell components. The gold standard of diagnosis is dependent on histomorphology and/or identification of t(12;16)(q13;p11) translocation by cytogenetics or demonstration of DDIT3 rearrangements by fluorescence in situ hybridization. There are currently no diagnostic immunohistochemical stains available. The broad range of myxoid neoplasms in the differential diagnosis includes a variety of sarcomas. Given the notable differences in disease biology among myxoid neoplasms, which range from benign to aggressive, an accurate diagnosis is imperative for proper treatment and prognostication. Prompted by our recent study showing frequent expression of the cancer testis antigen NY-ESO-1 in myxoid and round cell liposarcomas, we sought to evaluate the utility of NY-ESO-1 as an immunohistochemical marker for myxoid and round cell liposarcoma among mesenchymal myxoid neoplasms within the differential diagnosis. Formalin-fixed, paraffin-embedded blocks were obtained for the following mesenchymal myxoid neoplasms (n ¼ 138): myxoid and round cell liposarcoma (n ¼ 38); well-differentiated liposarcoma (n ¼ 12); lipoma (n ¼ 20; 4 with myxoid change); extra-cardiac soft tissue myxoma (n ¼ 39); extraskeletal myxoid chondrosarcoma (n ¼ 12); myxofibrosarcoma (n ¼ 10: 5 low grade, 2 intermediate grade, 3 high grade); and low-grade fibromyxoid sarcoma (n ¼ 7). Utilizing standard immunohistochemistry protocols, full sections were stained with NY-ESO-1 (clone E978), and staining was assessed for intensity (1-2 þ ), percentage of tumor positivity, and location. In all, 36/38 (95%) of the myxoid and round cell liposarcomas demonstrated NY-ESO-1 immunoreactivity. The majority of the positive cases (34/36; 94%) showed strong, homogenous staining (450% tumor positivity), and two cases (6%) showed weak (1 þ intensity), patchy staining (20-30% tumor positivity). Immunoreactivity was predominantly cytoplasmic. All the other neoplasms evaluated were negative for NY-ESO-1. NY-ESO-1 appears to be a sensitive and a specific marker for myxoid and round cell liposarcoma among mesenchymal myxoid neoplasms. The assessment of NY-ESO-1 expression by immunohistochemistry in the appropriate setting provides a cheaper, faster, and more accessible confirmatory test. Modern Pathology (2013Pathology ( ) 26, 1204Pathology ( -1210 doi:10.1038/modpathol.2013 published online 19 April 2013 Keywords: differential diagnosis; immunohistochemistry; mesenchymal myxoid neoplasms; myxoid and round cell liposarcomas; NY-ESO-1Myxoid and round cell liposarcomas constitute approximately one-third of all liposarcomas, a relatively common group of fat-derived soft tissue sarcomas. 1 The peak incidence of myxoid and round cell liposarcoma is in the fifth decade, and it preferentially involves the lower extremities. 2 The ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms

Hemminger

Iwenofu

2013

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…In a subset of tumors, NY-ESO-1 expression has been shown to be lost during remission which is thought to be either a means to evade T-cell-based immunosurveillance or the result of reduced cell proliferation. In hepato cellular carcinoma NY-ESO-1 expression has been associated with metastasis [60,61] and worse outcome following surgery with the possible mechanism of increasing tumor cell migration [62]. In gastrointestinal stromal tumors, the expression of NY-ESO-1 has been associated with tumor progression under imatinib treatment [63].…”

Section: Ny-eso-1 Expression Pattern In Tumorsmentioning

confidence: 99%

New York Esophageal Squamous Cell Carcinoma-1 and Cancer Immunotherapy

Esfandiary

Ghafouri‐Fard

2015

Immunotherapy

View full text Add to dashboard Cite

New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a known cancer testis gene with exceptional immunogenicity and prevalent expression in many cancer types. These characteristics have made it an appropriate vaccine candidate with the potential application against various malignancies. This article reviews recent knowledge about the NY-ESO-1 biology, function, immunogenicity and expression in cancers as well as and the results of clinical trials with this antigen.

show abstract

“…Interestingly, NY-ESO-1 expression correlates with a reduced recurrence-free survival after tumor resection. A possible explication is the increased migration capacity of NY-ESO-1 expressing cells as it has been described for NY-ESO-1 expressing HepG2 cell lines [32] . Overexpression of SSX has been described for several tumor types; however, the actual percentage of HCC expressing SSX varies between different study cohorts and SSX subtypes.…”

Section: Antitumoral Immune Responsesmentioning

confidence: 99%

Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma

Schmidt¹,

Thimme²

2016

Dig Dis

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide with a high mortality. The available treatment options are limited, thus the development of new therapeutic approaches is of a high clinical significance. Key Messages: The immune system plays a central role in the pathogenesis of HCC by supporting tumor growth, tumor survival, angiogenesis and the development of vascular infiltration and metastasis. In contrast, the immune system also exhibits a protective role in tumor surveillance, and specific CD8⁺ T-cells can be detected for various tumor-associated antigens. However, antitumoral potential of the immune system is limited by various inhibitory mechanisms, for example, an impaired priming and activation of CD8⁺ T-cells, inhibitory cells (e.g., regulatory T-cells) or the expression of inhibitory receptors (e.g., programmed cell death-1 and cytotoxic T-lymphocyte antigen-4). Immunotherapeutic strategies addressing these inhibitory mechanisms, for example, by providing a source of tumor antigens, depleting immunosuppressive cells or blocking inhibitory receptors, aim to induce and boost naturally occurring antitumoral immune responses. Conclusion: HCC is a tumor with a high incidence and mortality in developing countries as well as in the Western world. Due to the immune system's central role in the pathogenesis and surveillance of HCC, immunotherapy is a new treatment option that has yielded first promising results.

show abstract

NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Cited by 23 publications

References 17 publications

NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms

NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms

New York Esophageal Squamous Cell Carcinoma-1 and Cancer Immunotherapy

Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma

Contact Info

Product

Resources

About